Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + TQB2868 + Ramucirumab in 2nd-line Advanced HCC
NCT06441019Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jul 2024
- Primary completion
- May 2025
- Modality
- Immunotoxins, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2868 in hepatocellular carcinoma (HCC), sponsored by Fudan University. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
TQB2868
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06441019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441019.